Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical AB has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Diamyd Medical AB did not have earnings to cover the interest expense.
Diamyd Medical AB's debt to revenue ratio for the quarter that ended in May. 2026 was 0.00.
As of today, Diamyd Medical AB's Altman Z-Score is -0.68.
Diamyd Medical AB (FRA:DMN) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Diamyd Medical AB has the Financial Strength Rank of 6.
Diamyd Medical AB Financial Strength Related Terms
FRA:DMN vs VRTX, REGN, RVMD: Financial Strength Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Financial Strength vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Financial Strength distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Diamyd Medical AB has a Z-score of -0.68, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -0.68 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (FRA:DMN) has a Financial Strength of 6 as of May. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Diamyd Medical AB and its competitors. This is 33% below median its historical median of 9.00. Over the past decade, Diamyd Medical AB's Financial Strength has ranged from 5.00 to 10.00.
Is Diamyd Medical AB's Financial Strength too high?
Diamyd Medical AB's current Financial Strength of 6 is 33% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, Diamyd Medical AB has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Financial Strength compare to VRTX and REGN?
Diamyd Medical AB's Financial Strength of 6 can be compared against companies in the Biotechnology industry. Historically, Diamyd Medical AB's own Financial Strength has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Biotechnology company?
A good Financial Strength depends on the Biotechnology industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Financial Strength is 6, which is 33% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.08 — trading 12.3% above its estimated fair value. The current Financial Strength is 6, which is 33% below median its 10-year median of 9.00. Diamyd Medical AB's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Financial Strength is 6 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued.
The current stock price of €0.08 is trading 12.3% above its estimated GF Value™ of €0.07.
GuruFocus considers Diamyd Medical AB to be Modestly Overvalued.
Key valuation signals for FRA:DMN:
Financial Strength: 6 (33% below median its 10-year median of 9.00)
GF Value™: €0.07 vs. price of €0.08 (12.3% above fair value)
No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
40GF Score
Get the complete analysis for FRA:DMN
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DMN has been successfully added to your 
